Table 1. Locoregional therapies for oligometastatic breast cancer liver tumors.
| Reference | Year | n | Treatment modality | OS | Other survival outcomes | AE rate |
|---|---|---|---|---|---|---|
| Vlastos et al 47 | 2004 | 31 | Resection | 63 mo | 2-y OS: 86% 5-y OS: 61% |
|
| Adam et al 4 | 2006 | 85 | Resection | 32 mo | 5-y OS: 37% | 22% any AE |
| Caralt et al 13 | 2008 | 12 | Resection | 1-y OS: 100% 3-y OS: 79% 5-y OS: 33% |
17% any AE | |
| van Walsum et al 48 | 2012 | 32 | Resection | 55 mo | 5-y OS: 37% | 34% any AE |
| Abbott et al 49 | 2012 | 86 | Resection | 57 mo | PFS: 14.2 mo | 21% any AE |
| Mariani et al 50 | 2013 | 51 | Resection | 3-y OS: 74% 5-y OS: 50% |
20% any AE | |
| Kim et al 14 | 2014 | 13 | Resection | 1-y OS: 83% 3-y OS: 49% |
||
| Margonis et al 51 | 2016 | 131 | Resection | 53 mo | 1-y OS: 99% 3-y OS: 75% |
23% any AE |
| Ruiz et al 12 | 2018 | 139 | Resection | 7-y OS: 76% 10-y OS: 36% |
25% any AE | |
| Ruiz et al 52 | 2018 | 662 | Resection | 82 mo | 3-y OS: 81% 5-y OS: 69% |
|
| Wieners et al 53 | 2011 | 41 | SBRT | 6-mo OS: 97% 12-mo OS: 79% 18-mo OS: 60% |
<2% grade 3 and higher AE | |
| Milano et al 16 | 2012 | 121 | SBRT | 2-y OS: 50% 2-y PFS: 26% 5-y OS: 28% 5-y PFS: 20% |
<1% grade 3 and higher AE | |
| Palma et al 17 | 2018 | 159 | SBRT | 20 mo | PFS: 15 mo | 30% grade 2 and higher AE |
| Milano et al 16 | 2018 | 48 | SBRT | 5-y OS: 31% 10-y OS: 17% |
||
| Mahadevan et al 54 | 2018 | 42 | SBRT | 21 mo | 1-y OS: 66% | |
| Onal et al 55 | 2018 | 22 | SBRT | 1-y OS: 85% 2-y OS: 57% |
||
| Sofocleous et al 21 | 2007 | 12 | RFA | 60 mo | 3-y OS: 70% 5-y OS: 30% |
|
| Jakobs et al 33 | 2008 | 43 | RFA | 59 mo | 7% major AE | |
| Meloni et al 23 | 2009 | 52 | RFA | 42 mo | 5-y OS: 32% | 4% minor AE |
| Veltri et al 56 | 2014 | 45 | RFA | 1-y OS: 90% 2-y OS: 58% 3-y OS: 44% |
10% any AE | |
| Kümler et al 57 | 2015 | 32 | RFA | 34 mo | 3% grade 3 and higher AE | |
| Barral et al 28 | 2016 | 50 | RFA/MWA/ Cryoablation | 1-y OS: 98% 2-y OS: 96% |
||
| Bai et al 58 | 2018 | 69 | RFA | 26 mo | 1-y OS: 82% 2-y OS: 50% 3-y OS: 25% 5-y OS: 11% |
1% grade 3 and higher AE |
| Ridouani et al 24 | 2020 | 35 | RFA/MWA/ Cryoablation | 70 mo | Time to progression: 11 mo | 8% any AE |
Abbreviations: AE, adverse event; MWA, microwave ablation; OS, overall survival; PFS, progression-free survival; RFA, radiofrequency ablation; SBRT, stereotactic body radiation therapy.
Notes: Selected studies are presented. Survival reported as median value from time of treatment; n indicates number of breast cancer patients studied.